AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Savara Inc.
Video analysis: SVRA
All videosNo video analysis for this stock yet. Request one from our team.
News: SVRA
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA
BlackRock Inc. acquired a new position in Savara Inc. (NASDAQ: SVRA) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,494,498 shares of the company's stock, valued at approximately $76,966,000. BlackRock Inc. owned approximately 6.10% of Savara at the end of
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA
Algert Global LLC boosted its position in Savara Inc. (NASDAQ: SVRA) by 53.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329,259 shares of the company's stock after purchasing an additional 464,645 shares during the quarter. Algert Global LLC
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA
Deutsche Bank AG purchased a new position in Savara Inc. (NASDAQ: SVRA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 864,956 shares of the company's stock, valued at approximately $5,328,000. Deutsche Bank AG owned about 0.42% of Savara as of its
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.“Collectively, these data show that molgramostim continues to improve lung function, exercise capacity, and quality of life in patients, while reductions in biomarkers of.
Savara Announces New Employment Inducement Grant
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to eight new employees who recently joined the Company. The inducement awards consist of options to purchase 74,500 shares of the Company's common stock and restricted stock units (RSUs).
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2026 and provided a business update. “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity,” said Matt Pauls, J.D., M.B.A., Chair and Chief Executive Officer, Savara. “Our focus is on the potential l.
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal near-term catalyst.
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has granted a patent covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). European patent No.4121000 provides protection for MOLBREEVI through March 2041. Separately, the Australian Patent Office has a.
